Monoquant is an Adelaide company which aims to commercialise intellectual property developed by the Minimal Residual Disease Group led by Professor Alec Morley and based at Flinders University. Commercialisation is by way of provision of products and services, and by licensing of intellectual property in the general area of molecular diagnostics.
Areas of research and provision of services and products include:
Scientific collaboration involves groups around Australia, and commercial collaboration involves companies in the United States. In December 2010, Monoquant licensed its intellectual property in the field of haematopathology to Invivoscribe.There is a long-standing collaboration between Monoquant, Professor Morley and Invivoscribe.